Spots Global Cancer Trial Database for ga101
Every month we try and update this database with for ga101 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients. | NCT02315768 | Chronic Lymphoc... | GA101 ibrutinib | 65 Years - | University of California, San Diego | |
| GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma | NCT02495454 | CD20 Positive D... Elderly Unfit P... | Ga101 | 65 Years - | Fondazione Italiana Linfomi - ETS | |
| Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma | NCT02689869 | Indolent Non-Ho... | Ibrutinib GA 101 | 18 Years - | Ludwig-Maximilians - University of Munich | |
| A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | NCT02406742 | Leukemia, Lymph... | CC-122 Ibrutinib Obinutuzumab | 18 Years - 79 Years | Celgene | |
| A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL. | NCT02417285 | Lymphoma, Large... Lymphoma, Non-H... | Obinutuzumab CC-122 | 18 Years - | Celgene | |
| GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma | NCT01659099 | Diffuse Large B... | GA101 Rituximab Doxorubicin Cyclophosphamid... Prednisone Bleomycin Vindesin Vincristine | 18 Years - 60 Years | The Lymphoma Academic Research Organisation | |
| Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | NCT05105841 | Chronic Lymphoc... Small Lymphocyt... | Venetoclax Ibrutinib Obinutuzumab | 20 Years - | AbbVie | |
| First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients ≥ 60 Years | NCT03492775 | Indolent Non-ho... | Obinutuzumab Bendamustine | 18 Years - | Ludwig-Maximilians - University of Munich | |
| Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma | NCT01889797 | Indolent Non-Ho... | Arm A: Rituxima... Arm B: GA101 | 18 Years - | PrECOG, LLC. | |
| GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma | NCT01659099 | Diffuse Large B... | GA101 Rituximab Doxorubicin Cyclophosphamid... Prednisone Bleomycin Vindesin Vincristine | 18 Years - 60 Years | The Lymphoma Academic Research Organisation | |
| Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) | NCT04895436 | Chronic Lymphoc... | Venetoclax Obinutuzumab | 18 Years - | AbbVie | |
| Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma | NCT02689869 | Indolent Non-Ho... | Ibrutinib GA 101 | 18 Years - | Ludwig-Maximilians - University of Munich | |
| Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma | NCT02689869 | Indolent Non-Ho... | Ibrutinib GA 101 | 18 Years - | Ludwig-Maximilians - University of Munich | |
| Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) | NCT04895436 | Chronic Lymphoc... | Venetoclax Obinutuzumab | 18 Years - | AbbVie | |
| Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | NCT05105841 | Chronic Lymphoc... Small Lymphocyt... | Venetoclax Ibrutinib Obinutuzumab | 20 Years - | AbbVie | |
| Phase II Trial GA101 Inbrutinib B CLL | NCT02666898 | Leukemia, Lymph... | GA101 Ibrutinib Cyclophosphamid... Fludarabine | 18 Years - | French Innovative Leukemia Organisation | |
| A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | NCT02406742 | Leukemia, Lymph... | CC-122 Ibrutinib Obinutuzumab | 18 Years - 79 Years | Celgene |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
